Enhancing Oral Performance of Paclitaxel Lipid‐mimic Prodrug via Modulating Type of Fatty Acids

Yi‐fan Miao,Qing Ye,Ming‐yang Zhang,Lin Gao,Xi‐yan Wang,Wen‐xin Zhong,Zi‐xuan Wang,Zhong‐gui He,Chu‐tong Tian,Jin Sun
DOI: https://doi.org/10.1002/adhm.202203118
IF: 10
2023-03-18
Advanced Healthcare Materials
Abstract:Owing to the serious clinical side effects of intravenous Taxol®, an oral chemotherapeutic strategy is expected to be promising for paclitaxel (PTX) delivery. However, its poor solubility and permeability, high first‐pass metabolism, and gastrointestinal (GI) toxicity need to be overcome. A triglyceride (TG)‐like prodrug strategy facilitates oral drug delivery by bypassing liver metabolism. However, the effect of fatty acids (FAs) in sn‐1,3 on the oral absorption of prodrugs remains unclear. Herein, we explored a series of TG‐mimetic prodrugs of PTX with different carbon chain lengths and degrees of unsaturation of FAs at the sn‐1,3 position in an attempt to enhance oral antitumor effect and to guide the design of TG‐like prodrugs. Interestingly, the different FA lengths exhibited great influence on in vitro intestinal digestion behavior, lymph transport efficiency, and up to 4‐fold differences in plasma pharmacokinetics. The prodrug with long‐chain FAs showed a more effective antitumor effect, whereas the degree of unsaturation had a negligible impact. Our findings illustrated how FAs structures affect the oral delivery efficiency of TG‐like PTX prodrugs and thus provide a theoretical basis for their rational design. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?